Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 15 von 39
European journal of hospital pharmacy. Science and practice, 2021-09, Vol.28 (5), p.276-279
2021
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Initial dosing of intermittent vancomycin in adults: estimation of dosing interval in relation to dose and renal function
Ist Teil von
  • European journal of hospital pharmacy. Science and practice, 2021-09, Vol.28 (5), p.276-279
Ort / Verlag
England: BMJ Publishing Group LTD
Erscheinungsjahr
2021
Quelle
MEDLINE
Beschreibungen/Notizen
  • ObjectivesDue to the high interindividual variability in vancomycin pharmacokinetics, optimisation of its dosing is still challenging. This study aimed to explore vancomycin pharmacokinetics in adult patients and to propose an easy applicable dosing nomogram for initial treatment.MethodsVancomycin pharmacokinetics was calculated in a two-compartmental model based on therapeutic drug monitoring data. A linear regression model was used to explore the relationship between vancomycin elimination half-life and glomerular filtration rate estimated according the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.ResultsIn the whole study population (n=66), vancomycin volume of distribution, clearance and half-life median (IQR) values were 0.69 (0.58–0.87) L/kg, 0.031 (0.022–0.050) L/h/kg and 14.4 (9.5–25.2) hours, respectively. Vancomycin half-life was associated with glomerular filtration rate (r2=0.4126, p<0.0001) according to the formula: t1/2 (h) = −0.247×eGFRCKD-EPI (mL/min/1.73 m2)+32.89. This relationship was used to construct a dosing nomogram.ConclusionsWe propose an easy-to-use dosing nomogram for vancomycin therapy initiation that allows individualisation of the dosing interval with respect to the administered dose size and functional renal status.
Sprache
Englisch
Identifikatoren
ISSN: 2047-9956
eISSN: 2047-9964
DOI: 10.1136/ejhpharm-2019-002013
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8403779

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX